Back

Empagliflozin improves diastolic function in obese ZSF1 rats by restoring the cardiac mitochondrial respiratory capacity.

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Heart failure with preserved ejection fraction: bench Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Antje Schauer

Heart Centre Dresden - Dresden Technical University Hospital, Dresden (Germany)

3 More presentations in this session

Presentation thumbnail
The SGLT2I Dapagliflozin reverses metabolic stress driving myocardial inflammation in a mouse model of heart failure with preserved ejection fraction: insights from single-cell RNA sequencing
Doctor C. Panico (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Diabetes and chronic kidney disease synergistically contribute to left ventricular diastolic dysfunction and coronary microvascular disease in swine
Mr J. Hamers (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Epicardial tissue derived leptin promotes myocardial injury in metabolic syndrome rats through PKC/NADPH oxidase/ROS pathway
Doctor H. Chen (Zhengzhou, CN)
Abstract Slides

Access the full session

Session thumbnail
Heart failure with preserved ejection fraction: bench

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?
thumbnail
Congress Session
Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources